Cyclacel Pharmaceuticals Inc. Stock
Our community identified positive and negative aspects for Cyclacel Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "EBIT Margin" as a plus for the Cyclacel Pharmaceuticals Inc. stock. On the other hand our users think that "Expected Cash Flow" could be a problem in the future.
Pros and Cons of Cyclacel Pharmaceuticals Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cyclacel Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 3.660% | 8.974% | 17.241% | -40.351% | -8.602% | -10.053% | -81.048% |
| Vaxart Inc. | -0.710% | -0.639% | -15.408% | -49.275% | -58.457% | -74.601% | -95.556% |
| Achieve Life Sciences Inc. | 1.550% | -1.382% | 1.552% | 1.290% | 10.098% | 62.459% | -37.200% |
Comments
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CYCC provided by MarketBeat